Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/461398


Almirall: Pharmavitae Profile


Description: This analysis examines the historical and forecast performance for Almirall in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope of this title:

Highlights of this title:

Reasons to order your copy:
Benchmark Almiralls performance against key rivals in the ethical pharmaceutical sector See how the companys growth prospects will be hampered by the patent expiries of its four key products: Prevencor, Ebastel, Dobupal and Plusvent


Contents:

Chapter 1.

Executive summary 4
Key findings 4
Historical and forecast ethical sales performance 5
Therapeutic strategy 6
Launch and expiry outlook 9
Externalization, geographic and molecule type strategies 11
Externalization strategy 12
Geographic strategy 13
Molecule type strategy 13
SWOT analysis 14
Strengths 14
Weaknesses 15
Opportunities 16
Threats 16

Chapter 2.

Corporate history 26
Key findings 26
Background 27
Key corporate developments 27
M&A history 28
Current corporate structure 28
Pharmaceuticals 28
Research 29
OTC 29
Current management team 29

Chapter 3.

Historical performance 30
Key findings 30
Introduction 31
Revenue and growth rate analysis, 2002-05 31
Revenue and growth rate vs. peer set 32
Product analysis, 2002-05 34
Growth drivers 34
Prevencor 34
Esertia 35
Ebastel 35
Growth resistors 36
Prisdal 36
Almax 36

Chapter 4.

Forecast performance 37
Key findings 37
Introduction 38
Revenue and growth rate, 2005-11 38
Product analysis, 2005-11 40
Growth drivers 46
Esertia 46
Plusvent 47
Almogran 47
Growth resistors 47
Prevencor 47
Dobupal 47
Astudal 48
Therapy area analysis, 2005-11 50
CNS 52
Respiratory 53
Cardiovascular 53
Therapy area focus 54
Launches and expiries analysis, 2005-11 57
Launch portfolio 57
Core portfolio 59
Expiry portfolio 61
Launch/core/expiry configuration 63
Externalization analysis, 2005-11 66
Geographic analysis, 2005-11 72
Molecule type analysis, 2005-11 75

Chapter 5.

Key products and competitors 80
Key findings 80
Overview 81
CNS 82
Esertia 82
Overview 82
Sales forecast 83
Competitive landscape 83
Amlogran 85
Overview 85
Sales forecast 86
Competitive landscape 86
Dobupal 88
Overview 88
Sales forecast 89
Competitive landscape 89
Respiratory 91
Plusvent 91
Overview 91
Sales forecast 92
Competitive landscape 92
Ebastel 94
Overview 94
Sales forecast 95
Competitive landscape 95
Cardiovascular 97
Prevencor 97
Overview 97
Sales forecast 98
Competitive landscape 98
Parapres 100
Overview 100
Sales forecast 101
Competitive landscape 101
Gastrointestinal 103
Opiren 103
Overview 103
Sales forecast 104
Competitive landscape 104
Almax 106
Overview 106
Sales forecast 107
Competitive landscape 107
R&D pipeline 108

Chapter 6.

Appendix 109
IMS vs. company-reported data reconciliation 109
Abbreviations 111
Exchange rates

List of Tables
Table 1: Almirall Corporate Executive Committee 29
Table 2: Mid Pharma Peer set overview 32
Table 3: Product portfolio overview, sales ($m), 2005-11 40
Table 4: Therapy area overview, sales ($m), 2005-11 50
Table 5: Launch portfolio overview, sales ($m), 2005-11 57
Table 6: Core portfolio overview, sales ($m), 2005-11 59
Table 7: Expiry portfolio overview, sales ($m), 2005-11 61
Table 8: Externally developed portfolio, 2005-11 ($m) 66
Table 9: Molecule type overview, sales ($m), 2005-11 75
Table 10: Key products overview 81
Table 11: Esertia: overview 82
Table 12: Esertia: sales forecast ($m), 2005-11 83
Table 13: Almogran: overview 85
Table 14: Esertia: sales forecast ($m), 2005-11 86
Table 15: Dobupal: overview 88
Table 16: Dobupal: sales forecast ($m), 2005-11 89
Table 17: Plusvent: overview 91
Table 18: Plusvent: sales forecast ($m), 2005-11 92
Table 19: Ebastel: overview 94
Table 20: Ebastel: sales forecast ($m), 2005-11 95
Table 21: Prevencor: overview 97
Table 22: Prevencor: sales forecast ($m), 2005-11 98
Table 23: Parapres: overview 100
Table 24: Parapres: sales forecast ($m), 2005-11 101
Table 25: Opiren: overview 103
Table 26: Opiren: sales forecast ($m), 2005-11 104
Table 27: Almax: overview 106
Table 28: Almax: sales forecast ($m), 2005-11 107
Table 29: Almiralls R&D pipeline (Phase I-registration) 108
Table 30: Exchange rates, 2005

List of Figures
Figure 1: Historical and forecast ethical sales performance (% CAGR), Almirall and Mid Pharma peer set 5
Figure 2: Therapeutic focus vs. Mid Pharma peer set (%), 2005 7
Figure 3: Launch, core and expiry, absolute sales growth, 2005-11 (sales as % of 2005 sales), Almirall 9
Figure 4: Launch, core and expiry, absolute sales growth, 2005-11 (sales as % of 2005 sales), peer set 10
Figure 5: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2005 11
Figure 6: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2011 12
Figure 7: SWOT analysis of Almirall 14
Figure 8: Revenue & growth rate (ethical sales) ($m), 2002-05 31
Figure 9: Ethical revenue ($m) and growth rate (%) vs. peer set, 2002-05 33
Figure 10: Growth drivers/resistor products of historical revenue performance ($m), 2002-05 34
Figure 11: Ethical revenue ($m) and growth rate (%), 2005-11 38
Figure 12: Leading products by sales ($m), 2005 43
Figure 13: Leading products by sales ($m), 2011 45
Figure 14: Growth drivers and resistors by product, 2005-11 46
Figure 15: Key strategic products, sales ($m), 2005-11 49
Figure 16: Ethical sales by therapy area ($m), 2005-11 51
Figure 17: Growth drivers and resistors by therapy area (%), 2005-11 52
Figure 18: Ethical sales by therapy area (%), 2005-11 54
Figure 19: Therapy area focus compared with peer set (% total ethical sales), 2005 55
Figure 20: Therapy area focus compared with peer set (% total ethical sales), 2011 56
Figure 21: Launch schedule, sales ($m), 2005-11 58
Figure 22: Core products sales growth ($m), 2005-11 60
Figure 23: Expiry schedule, sales ($m), 2005-11 62
Figure 24: Launch, core and expiry, sales ($m), 2005-11 63
Figure 25: Launch, core and expiry, absolute sales growth, 2005-11 (sales as % of 2005 sales), Almirall 64
Figure 26: Launch, core and expiry, absolute sales growth, 2005-11 (sales as % of 2005 sales), peer set 65
Figure 27: Externalization dependency, sales ($m), 2005-11 68
Figure 28: Growth drivers and resistors, externally vs. internally discovered products, sales ($m), 2005-11 69
Figure 29: Externalization dependency vs. peer set, % total sales, 2005 70
Figure 30: Externalization dependency vs. peer set, % total sales, 2011 71
Figure 31: Geographical sales breakdown ($m), 2005-11 72
Figure 32: Growth drivers and resistors by geography, sales ($m), 2005-11 73
Figure 33: US dependency vs. peer set, % total sales, 2005 74
Figure 34: US dependency vs. peer set, % total sales, 2011 75
Figure 35: Molecule type sales breakdown ($m), 2005-11 76
Figure 36: Growth drivers and resistors by molecule type, sales ($m), 2005-11 77
Figure 37: Biologics dependency vs. peer set, % total sales, 2005 78
Figure 38: Biologics dependency vs. peer set, % total sales, 2011 79
Figure 39: IMS vs. company-reported ethical sales discrepancy ($m), 2005 110
Figure 40: IMS vs. company-reported ethical sales forecast growth rates (%), 2005-11 111




Ordering: Order Online - visit http://www.researchandmarkets.com/reports/461398

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 08/09/2008 03:55:26
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com


Order information

Please verify that the product information is correct and select the format you require.

Product Name:
Almirall: Pharmavitae Profile
Web Address:
http://www.researchandmarkets.com/reports/461398
Office Code:
OCHHIJRNSQW

Report formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €6,099.00




Contact information

Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Research and Markets Page 2 of 2
Printed 08/09/2008 03:55:26

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder Name:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.


If you have a Marketing Code please enter it below:

Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp



Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World